© 2026 Michigan State University Board of Trustees
Public Media from Michigan State University
DONATE
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

NPR | By Sydney Lupkin,
Steve Inskeep
Published May 22, 2026 at 4:44 AM EDT

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Copyright 2026 NPR
Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
See stories by Sydney Lupkin
Steve Inskeep
Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.
See stories by Steve Inskeep
SUSTAIN what matters. BUILD what’s next.
With federal funding eliminated, WKAR relies more than ever on community support to sustain essential services that remain freely available to everyone in mid-Michigan. Your support helps shape what comes next for public media in our region. The best way to support WKAR is by becoming a sustaining member today or by upgrading your current gift. Support WKAR TV Here | Support WKAR Radio Here.